{
    "clinical_study": {
        "@rank": "146305", 
        "arm_group": {
            "arm_group_label": "MSCs injection", 
            "arm_group_type": "Experimental", 
            "description": "Injection of autologous bone marrow-derived mesenchymal cells"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of intracoronary injection of mesenchymal\n      stem cells (MSCs) to repair heart function in patients with myocardial ischemia."
        }, 
        "brief_title": "Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ischemic heart disease is a major public health problem in the industrialized and developing\n      world. Current research is focusing on the development of cell-based therapies using stem\n      cells to treat heart failure. Mesenchymal stem cells (MSCs) can differentiate into\n      endothelial cells and participate in the development of new blood vessels in the heart\n      damaged. Therefore, MSCs has shown promise for heart repair. The investigators study will\n      evaluate the safety and efficacy of intracoronary injection of mesenchymal stem cells (MSCs)\n      to repair heart function in patients with myocardial ischemia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic coronary artery disease\n\n          -  NYHA (Heart failure) Class II-IV or Angina pectoris CCS Class III or IV or symptoms\n             consistent with.\n\n          -  Ejection fraction between 35% and 55%.\n\n          -  Stable medical therapy for at least one month\n\n          -  Patients clinically treated with coronary angioplasty with or without intraluminal\n             stent.\n\n          -  Patients with surgical revascularization and without the possibility of new invasive\n             intervention.\n\n        Exclusion Criteria:\n\n          -  Human immunodeficiency virus (HIV1-2), HTLV-1 and 2.\n\n          -  An active uncontrolled infection.\n\n          -  Pregnancy.\n\n          -  Mental disability.\n\n          -  Terminal illnesses.\n\n          -  Valvular heart disease, congenital heart disease or other causes of cardiomyopathy\n             than ischemic.\n\n          -  Life perspective by other diseases under 1 year.\n\n          -  History of severe arrhythmias\n\n          -  Renal dysfunction or against medication\n\n          -  Inability to perform cardiac catheterization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913886", 
            "org_study_id": "MSC_Isquemica"
        }, 
        "intervention": {
            "arm_group_label": "MSCs injection", 
            "description": "MSCs cells will be injected in two aliquots of 10 ml by catheterism", 
            "intervention_name": "MSCs injection", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cardiovascular Diseases", 
            "Myocardial Ischemia", 
            "Coronary Artery Disease", 
            "Heart Diseases", 
            "Coronary Disease", 
            "Ventricular Dysfunction", 
            "Arteriosclerosis"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "carmen.rebelatto@pucpr.br", 
                "last_name": "Carmen Rebelatto, PhD", 
                "phone": "+55 41 32712219"
            }, 
            "facility": {
                "address": {
                    "city": "Curitiba", 
                    "country": "Brazil", 
                    "state": "Paran\u00e1"
                }, 
                "name": "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1"
            }, 
            "investigator": {
                "last_name": "Paulo Brofman, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Autologous Grafting of Mesenchymal Stem Cells in Severe Refractory Ischemic Cardiomyopathy", 
        "overall_contact": {
            "email": "paulo.brofman@pucpr.br", 
            "last_name": "Paulo Brofman, PhD", 
            "phone": "+55 41 3271 2219"
        }, 
        "overall_contact_backup": {
            "email": "alexandra.senegaglia@pucpr.br", 
            "last_name": "Alexandra Senegaglia, PhD", 
            "phone": "+55 41 3271 2219"
        }, 
        "overall_official": {
            "affiliation": "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1", 
            "last_name": "Paulo Brofman, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913886"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1", 
            "investigator_full_name": "Danielle Malheiros", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measures by specific questionnaire of quality of life: Minnesota Living with Heart Failure Questionnaire (MLHFQ)", 
                "measure": "Change in quality of life", 
                "safety_issue": "No", 
                "time_frame": "3 months, 6 months, 12 months"
            }, 
            {
                "measure": "Changes in exercise capacity", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Changes in plasma inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Santa Casa de Miseric\u00f3rdia de Curitiba, Brazil", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Funda\u00e7\u00e3o Arauc\u00e1ria, Brazil", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Danielle Malheiros", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}